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Abstract
Activation of the IKK-NFkB pathway increases the resistance of cancer cells to ionizing radiation (IR). This effect has been
largely attributed to the induction of anti-apoptotic proteins by NFkB. Since efficient repair of DNA double strand breaks
(DSBs) is required for the clonogenic survival of irradiated cells, we investigated if activation of the IKK-NFkB pathway also
regulates DSB repair to promote cell survival after IR. We found that inhibition of the IKK-NFkB pathway with a specific IKKb
inhibitor significantly reduced the repair of IR-induced DSBs in MCF-7 cells. The repair of DSBs was also significantly
inhibited by silencing IKKb expression with IKKb shRNA. However, down-regulation of IKKa expression with IKKa shRNA had
no significant effect on the repair of IR-induced DSBs. Similar findings were also observed in IKKa and/or IKKb knockout
mouse embryonic fibroblasts (MEFs). More importantly, inhibition of IKKb with an inhibitor or down-regulation of IKKb with
IKKb shRNA sensitized MCF-7 cells to IR-induced clonogenic cell death. DSB repair function and resistance to IR were
completely restored by IKKb reconstitution in IKKb-knockdown MCF-7 cells. These findings demonstrate that IKKb can
regulate the repair of DSBs, a previously undescribed and important IKKb kinase function; and inhibition of DSB repair may
contribute to cance cell radiosensitization induced by IKKb inhibition. As such, specific inhibition of IKKb may represents a
more effective approach to sensitize cancer cells to radiotherapy.
Citation: Wu L, Shao L, An N, Wang J, Pazhanisamy S, et al. (2011) IKKb Regulates the Repair of DNA Double-Strand Breaks Induced by Ionizing Radiation in MCF-7
Breast Cancer Cells. PLoS ONE 6(4): e18447. doi:10.1371/journal.pone.0018447
Editor: Janine Santos, University of Medicine and Dentistry of New Jersey, United States of America
Received February 1, 2011; Accepted February 28, 2011; Published April 7, 2011
Copyright:  2011 Wu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported in part by grants from the National Institutes of Health (R01CA086688, CA102558 and AI080421), the Winthrop W. Rockefeller
Endowment for Leukemia Research and the Arkansas Research Alliance Scholarship from the Arkansas Science & Technology Authority to DZ. The funders had no
role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: dzhou@uams.edu
. These authors contributed equally to this work.
Introduction
The IkB kinase (IKK)-nuclear factor kB (NFkB) pathway is one
of the most important cellular signal transduction pathways [1]. It
consists of members of the NFkB family and the family of
inhibitors of NFkB( I kB), the IkB kinase (IKK) complex, and
various other regulatory components. The NFkB family includes
RelA (p65), RelB, c-Rel, NFkB1/p105 (p50 precursor), and
NFkB2/p100 (p52 precursor); the IkB family consists of IkBa,
IkBb,I kBe, Bcl-3, p100/IkBd, and p105/IkBc; and the IKK
complex is composed of two catalytic subunits, IKKa and IKKb,
and the regulatory subunit IKKc. Normally, members of the
NFkB family form a heterodimer/homodimer that resides in the
cytoplasm as an inactive complex in association with a member of
the IkB family. Upon stimulation with an inflammatory stimulus,
the so-called canonical or classical pathway is activated, leading to
the activation of IKK complex. Activated IKKa and/or IKKb
phosphorylate IkBa at S-32 and S-36. This causes IkBa
ubiquitination and degradation by the S26 proteasome, thereby,
allowing NFkB to translocate into the nucleus to regulate NFkB
target genes. Through regulation of its target genes, NFkB can
regulate various physiologic processes such as cell proliferation,
migration and survival.
In addition, an increasing body of evidence suggests that
activation of the IKK-NFkB pathway also play a pivotal role in the
development of cancer resistance to ionizing radiation (IR) and
chemotherapy [2–5]. This is because IR and many chemother-
apeutic agents can activate NFkB through the atypical NFkB
activation pathway by induction of DNA double-strand breaks
(DSBs) [6,7]. DSBs can activate ataxia telangiectasia mutated
(ATM) that in turn phosphorylates IKKc at Ser85. This leads to
IKKc mono-ubiquitination and translocation into the cytoplasm,
where IKKc remains associated with ATM to activate IKKa and/
or IKKb. It has been shown that activation of the IKK-NFkB
pathway renders many types of tumor cells more resistant to IR
and chemotherapy presumably via induction of anti-apoptotic
proteins [2–5]. Therefore, inhibition of the NFkB transcriptional
activity has been extensively exploited as a novel approach to
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18447sensitize cancers to radiotherapy and chemotherapy, but has
achieved mixed results [2–5]. Therefore, further studies are
urgently needed to gain a better understanding on how activation
of the IKK-NFkB pathway regulates tumor cell sensitivity to IR
and chemotherapy before a molecular targeted therapy against the
IKK-NFkB pathway can be effectively employed for cancer
treatment.
It has been well established that IR kills cancer cells primarily by
induction of DSBs and efficient repair of DSBs is required for the
clonogenic survival of irradiated cells [8,9]. Therefore, we
hypothesized that activation of the IKK-NFkB pathway by IR
may also promote cancer cell survival in part by regulating the
repair of DSBs. To test this hypothesis, we first used BMS-345541
(BMS), a specific IKKb inhibitor [10], to selectively inhibit the
IKK-NFkB pathway and found that it could significantly inhibit
the repair of IR-induced DSBs in MCF-7 human breast cancer
cells and H1299 and H1648 human lung cancer cells. Interest-
ingly, the repair of IR-induced DSBs in MCF-7 cells was not
affected by down-regulation of IKKa, but was significantly
inhibited by IKKb knockdown. In addition, the suppression of
DSB repair by knockdown or inhibition of IKKb was associated
with an increased sensitivity of MCF-7 cells to IR. DSB repair
function and resistance to IR were completely restored in IKKb-
knockdown MCF-7 cells after reconstitution with an active form of
IKKb. To our knowledge, this is the first study demonstrating that
activation of the IKK-NFkB pathway by IR can regulate the
repair of DSBs and inhibition of IKKb activity may sensitize
cancer cells to IR at least in part via inhibition of DSB repair.
Therefore, specific inhibition of IKKb represents a more effective
approach to sensitize cancer cells to radiotherapy.
Results
IKKb inhibition suppresses the repair of IR-induced DSBs
Activation of NFkB by IR depends on IKKb [6]. BMS is a
potent and specific IKKb inhibitor and can effectively inhibit
NFkB activation induced by diverse stimuli [10]. Therefore, we
treated MCF-7 cells with BMS to determine whether activation of
the IKKb-NFkB pathway regulates the repair of IR-induced DSBs
by cH2AX foci assay [11]. As shown in Figure 1 A, MCF-7 cells
exhibited a low level of DSBs prior to exposure to IR. The basal
levels of DSBs were not significantly changed after incubation with
BMS (p.0.05). Exposure to IR increased DSBs in MCF-7 cells
and the increases were comparable in the cells treated with vehicle
or BMS 1 hr after IR when the formation of cH2AX foci reached
the peak level (Figure 1 A). The numbers of cH2AX foci in
vehicle-treated cells declined rapidly thereafter and were almost
back to the basal level at 6 hr after IR, indicating that these cells
can efficiently repair IR-induced DSBs. In contrast, the numbers
of cH2AX foci in BMS-treated cells remained significantly
elevated 6 hr after IR. Moreover, even up to 24 hr after IR
MCF-7 cells treated with 5 mM BMS still exhibited a significant
Figure 1. IKKb inhibitor suppresses the repair of IR-induced DSBs. MCF-7 cells were incubated with vehicle (0.1% DMSO) or 2.5 and 5 mM
BMS-345541 (BMS) for 1 h before exposure to 2 Gy IR. DSBs were analyzed by cH2AX and 53BP1 immunofluorescent staining at various time points
after IR. (A) Representative photomicrographs (1006magnifications) of cH2AX immunofluorescent staining (red) and nucleic counterstaining with
Hoechst-33342 (blue) are shown in the left panel and the average numbers of cH2AX foci/cell from three independent experiments are presented in
the right panel. (B) Representative photomicrographs (1006 magnifications) of 53BP1 immunofluorescent staining (green) and nucleic
counterstaining with Hoechst-33342 (blue) are shown in the left panel and the average numbers of 53BP1 foci/cell from three independent
experiments are presented in the right panel. The data are presented as mean 6 SE. * p,0.05, ** p,0.01, and *** p,0.001, vs. vehicle.
doi:10.1371/journal.pone.0018447.g001
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the formation of 53BP1 foci was used as an alternative surrogate to
quantify IR-induced DSBs, as 53BP1 can be rapidly recruited by c
H2AX to the sites of DSBs to form 53BP1 foci (Figure 1 B) [12].
These findings demonstrate that BMS can inhibit the repair of IR-
induced DSBs in MCF-7 cells. To determine whether the effect of
BMS is specific to MCF-7 cells and whether other IKKb inhibitors
have a similar effect as BMS, we extended the studies to two
additional human lung cancer cell lines H1299 and H1648 and
two other potent IKKb inhibitors SC-514 [13] and TPCA-1 [14]
and observed similar results as seen in MCF-7 cells treated with
BMS (Figure 2). However, among these inhibitors examined, BMS
is the most potent inhibitor of DSB repair.
BMS is equally potent as DNA-dependent protein kinase
(DNA-PK) and ATM inhibitors in inhibition of DSB repair
NU7026 (NU) and KU55933 (KU) are well characterized
DNA-PK and ATM inhibitors, respectively [15,16]. Both of them
can potently inhibit DSB repair and sensitize various tumor cells to
IR. Therefore, we compared the inhibitory effect of BMS with
these of NU and KU on the repair of IR-induced DSBs. As shown
in Figure 3 A and B, MCF-7 cells exhibited similar increases in
cH2AX and 53BP1 foci 1 hr after IR in regardless of their pre-
treatment. At 6 hr after IR, the majority of IR-induced DSBs were
repaired in vehicle-treated MCF-7 cells, whereas significantly
fewer DSBs were repaired in the cells treated with BMS, NU or
KU. Even at 24 hr after IR, substantial DSBs remained
unrepaired in MCF-7 cells treated with BMS and NU. These
findings demonstrate that BMS is equally potent as DNA-PK and
ATM inhibitors in inhibition of the repair of IR-induced DSBs.
Although BMS is a selective inhibitor of IKKb, it is not know
whether it inhibits DNA-PK and ATM [10]. Therefore, we
examined the effects of BMS on DNA-PK and ATM in in vitro
kinase assays. As shown in Figure 3 C and D, 5 mM NU and KU
almost completely inhibited the kinase activities of DNA-PK and
ATM, respectively. However, the same concentration of BMS had
no such effect. Even at a higher concentration (10 mM), the kinase
activities of DNA-PK and ATM remained unaffected by BMS.
This result suggests that the inhibition of DSB repair by BMS is
unlikely attributed to a non-specific inhibition of DNA-PK and
ATM.
IKKb is essential for efficient repair of IR-induced DSBs
To further explore the requirement of IKK in efficient DSB
repair, we generated stable IKKa and/or IKKb knockdown cell
lines, e.g. IKKa(-), IKKb(-), and IKKa/b(-) cells, by transfection
of MCF-7 cells with lentiviral short hairpin RNAs (shRNAs) that
specifically target IKKa and/or IKKb mRNA. As shown in
Figure 4 A–C, down regulation of IKKa and/or IKKb expression
significantly inhibited IR-induced NFkB activation. Interestingly,
Figure 2. Effects of different IKKb inhibitors on DSB repair in different cancer cell lines. (A) and (B) MCF-7 cells were incubated with
vehicle (0.1% DMSO), 5 mM BMS-345541 (BMS), 5 mM TPCA-1 or 25 mM SC514 for 1 h before exposure to 2 Gy IR. DSBs were analyzed by cH2AX and
53BP1 immunofluorescent staining at various time points after IR. Un-irradiated cells were included as controls (CTL). The average numbers of cH2AX
and 53BP1 foci/cell from three independent experiments are presented as mean 6 SE. (C) and (D) H1299 and H1648 cells were incubated with vehicle
(0.1% DMSO) or 5 mM BMS-345541 (BMS), 5 mM TPCA-1 or 25 mM SC514 for 1 h before exposure to 2 Gy IR. DSBs were analyzed by cH2AX
immunofluorescent staining at various time points after IR. The average numbers of cH2AX foci/cell from three independent experiments are
presented as mean 6 SE. *p,0.05, **p,0.01, and *** p,0.001, vs. vehicle.
doi:10.1371/journal.pone.0018447.g002
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significant reduction in the repair of IR-induced DSBs (Figure 4 D
and F). These findings suggest that IKKb, but not IKKa is
essential for DSB repair, which was confirmed by the observations
from IKKa and/or IKKb knockout mouse embryonic fibroblasts
(MEFs) as well (Figure S1).
To further validate the essential role of IKKb in DSB repair
and determine whether the kinase activity of IKKb is required for
the regulation, we reconstituted MCF-7/IKKb(-) cells with wild-
type IKKb (WT- IKKb), kinase-dead IKKb (K44M-IKKb), and
constitutively active IKKb (SSEE-IKKb) [17] by lentiviral
transfection. The expression of these respective transgenes was
confirmed by Western blot as shown in Figure 5 A. As reported in
a previous study the cells transfected with WT-IKKb exhibited
constitutive activation of the NFkB pathway as those transfected
with SSEE-IKKb [17] and the activation could not be
augmented by IR (Figure 5 A and B). In contrast, the cells
transfected with K44M-IKKb exhibited a similar deficiency in
NFkB activation as vector-transfected MCF-7/IKKb(-) cells. The
DSB repair function was completely restored in MCF-7/IKKb(-)
after transfection with either WT-IKKb or SSEE-IKKb
compared to MCF-7 cells, while MCF-7/IKKb(-)/K44M-IKKb
cells remained deficient in the repair of IR-induced DSBs as
vector-transfected MCF-7/IKKb(-) cells (Figure 5 C and D).
These results along with the data from BMS experiments
confirmed that IKKb is critical for DSB repair and its kinase
activity is indispensable for this function.
Inhibition of IKKb sensitizes MCF-7 cells to IR
Since efficient repair of IR-induced DSBs is required for the
clonogenic survival of irradiated cells [8,9], we hypothesized that
suppression of DSB repair via inhibition of IKKb kinase activity
can sensitize tumor cells to IR. To test this hypothesis, we exposed
MCF-7, MCF-7/IKKa(-), MCF-7/IKKb(-), and MCF-7/IKKa/
b(-) cells to 0, 1, 2 and 3 Gy IR, which led to a dose-dependent
reduction in their survival rate (Figure 6 A). The reduction was
greater in MCF-7/IKKb(-) and MCF-7/IKKa/b(-) cells than that
in MCF-7 and MCF-7/IKKa(-) cells. Reconstitution of MCF-7/
IKKb(-) with WT-IKKb or SSEE-IKKb restored their resistance
to IR, whereas MCF-7/IKKb(-)/K44M-IKKb cells remained
equally sensitive to IR as vector-transfected MCF-7/IKKb(-) cells
(Figure 6 B). In addition, pharmacological inhibition of IKKb
kinase activity with BMS also sensitized MCF-7 cells to IR-
induced clonogenic cell death (Figure 6 C). These findings suggest
that inhibition of IKKb activity sensitizes MCF-7 cells to IR at
least in part via inhibition of DSB repair. Altogether our data
support the notion that activation of IKKb promotes the repair of
DSBs and suppression of IKKb activity inhibits the repair of IR-
induced DSBs and sensitizes certain cancer cells to IR-induced cell
death.
Figure 3. IKKb inhibitor is equally potent as DNA-PK and ATM inhibitors in inhibition of the repair of IR-induced DSBs. (A) and (B)
MCF-7 cells were incubated with vehicle (0.1% DMSO) or 5 mM BMS-345541 (BMS), NU-7026 (NU) or KU-55933 (KU) for 1 h before exposure to 2 Gy IR.
DSBs were analyzed by cH2AX and 53BP1 immunofluorescent staining before IR (CTL) or at various time points after IR. The average numbers of
cH2AX and 53BP1 foci/cell from three independent experiments are presented as mean 6 SE. *** p,0.001, vs. vehicle. (C) DNA-PK kinase activity
assay. The kinase activity was calculated according to the radioactivity of the c-
32P-substrate. The data are presented as mean 6 SE (n=3).
*** p,0.001, vs. vehicle. (D) ATM kinase activity assay. A representative of c-
32P-H2AX autoradiography and ATM Western blot is shown. Similar
results were observed in two additional experiments.
doi:10.1371/journal.pone.0018447.g003
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IR is one of the most widely used therapeutic modalities for
cancer. Unfortunately, many tumor cells are inherently more
resistant to IR or can acquire radioresistance shortly after
radiotherapy, which inevitably leads to treatment failure and
relapse of the disease [4]. An accumulating body of evidence
suggests that constitutive activation of the IKK-NFkB pathway
can contribute to cancer development, progression and resistance
to cancer therapy [2,3], whereas activation of this pathway by IR
can also render tumor cells more resistant to radiotherapy [4].
Therefore, inhibition of the IKK-NFkB pathway has the potential
to increase the therapeutic index of radiotherapy [4].
Among various inhibitors of the IKK-NFkB pathway, IKKb
inhibitors have emerged as the most promising anti-tumor agents
and novel tumor sensitizers for IR and chemotherapy [13].
However, the mechanisms of their action have not been well
studied but are presumably attributed to the inhibition of NFkB
activity, which can increase tumor cell apoptosis by reducing the
expression of anti-apoptotic proteins. The results from our studies
reveal that IKKb inhibitors can also inhibit the repair of IR-
induced DSBs. This effect is not due to a non-specific inhibition of
DNA-PK and ATM but specific inhibition of IKKb, because DSB
repair was also significantly inhibited by silencing IKKb
expression but not by IKKa knockdown and the repair function
was restored after reconstitution of a functional IKKb. Therefore,
our results revealed a previously undescribed and important IKKb
kinase function, e.g. regulation of DSB repair.
It has been well established that IR kills cancer cells primarily by
induction of DSBs. DSBs are considered the most detrimental
Figure 4. IKKb is essential for the repair of IR-induced DSBs. (A) Down-regulation of IKKa and/or IKKb expression in MCF-7 cells by shRNA was
confirmed by Western blot analysis. (B) Down-regulation of IKKa and/or IKKb expression by shRNA inhibits IR-induced phosphorylation of IkBa in
MCF-7 cells. The levels of phosphorylated IkBa (p-IkBa) in the lysates from vector- or IKKa and/or IKKb shRNA-transfected MCF7 cells before (CTL) or
30 min after IR (2 Gy) were analyzed by Western blots. (C) Down-regulation of IKKa and/or IKKb expression by shRNA inhibits IR-induced NFkB
activation in MCF-7 cells. NFkB activation was analyzed by quantification of the levels of RelA in the nuclear extracts from vector- or IKKa and/or IKKb
shRNA-transfected MCF7 cells before (CTL) or 30 min after IR (2 Gy) by an ELISA assay. The data are presented as mean 6 SE (n=3). *** p,0.001, vs.
CTL. (D)-(F) Down-regulation of IKKb but not IKKa expression by shRNA inhibits the repair of IR-induced DSBs in MCF-7 cells. DSBs were analyzed by
cH2AX and 53BP1 immunofluorescent staining at 1 h and 6 h after vector- or IKKa and/or IKKb shRNA-transfected MCF7 cells were exposed to 2 Gy
IR. Un-irradiated cells were included as controls (CTL). Representative photomicrographs (1006magnifications) of cH2AX (red) and 53BP1 (green)
immunofluorescent staining and nucleic counterstaining with Hoechst-33342 (blue) are shown in (D) and the average numbers of cH2AX and 53BP1
foci/cell from three independent experiments are presented (E) and (F) as mean 6 SE. ** p,0.01, and *** p,0.001, vs. vector-transfected cells.
doi:10.1371/journal.pone.0018447.g004
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Therefore, targeted inhibition of the DSB repair pathways has
been actively pursued as a way to sensitize tumor cells to IR and
other chemotherapeutic agents [8,9]. KU-55933 and NU-7026
are two well studied tumor sensitizers that inhibit DSB repair by
targeting ATM and DNA-PK, respectively [15,16]. We found that
the potency of the IKKb inhibitor BMS in inhibiting DSB repair is
comparable to that of KU and NU. Since IKKb inhibitors such as
BMS can inhibit not only DSB repair but also NFkB-mediated
induction of anti-apoptotic proteins [2,3,18], they are potentially
more advantageous than ATM and DNA-PK inhibitors as a
radiosensitizer. Interestingly, even though BMS is cytotoxic to
some tumor cells and can sensitize MCF-7 human breast cancer
cells to IR, it is a relatively safe agent that does not cause
noticeable normal tissue damage in vivo [19–21]. These findings
highlight the therapeutic potential of IKKb inhibitors as an anti-
tumor agent and a tumor sensitizer.
The mechanisms by which IKKb regulates DSB repair have
yet to be elucidated. Our preliminary data showed that selective
inhibition of the NFkB transcriptional activity by ectopical
expression of a mutant IkBa or down-regulation of RelA by
RNAi had no effect on the repair of IR-induced DSBs (Figure
S2), indicating that the induction of NFkB-RelA activity is not
required for the regulation of DSB repair. However, it remains to
be determined if activation of the other members of the NFkB
family by IKKb, such as c-Rel, may be involved in the regulation
of DSB repair. For example, a recent report showed that
activation of IKKb up-regulates the expression of Claspin via c-
Rel [22]. Claspin can regulate DNA damage-activated check-
point response by promoting ataxia telangiectasia and Rad3-
related protein (ATR)-mediated Chk1 phosphorylation and
activation [23,24]. However, it may not be unexpected to find
that IKKb may regulate DSB repair independent of NFkB,
because several non-IkB targets of IKKb have been identified
recently [25,26]. For example, it has been shown that IKKb can
directly phosphorylate Aurora kinase A to regulate its stability for
the maintenance of bipolar sindle assembly and genomic stability
[23]. In addition, a recent study showed that IKKb translocates
to the nucleus following UV irradiation [27]. It is plausible that
IKKb enters the nucleus following IR treatments to assist DSB
repair processes. Alternatively, it will be interesting to determine
if IKKb-dependent DSB repair could be initiated by a
mechanism involving the cytoplasmic IKKb-ATM axis [6,7,28].
Identification of IKKb substrate(s) required for DSB repair and
elucidation of the mechanisms by which IKKb regulates DSB
repair will therefore opens up a new model of DNA damage
response in mammalian cells, which will be investigated in our
future studies.
Figure 5. Reconstitution of IKKb to MCF-7/IKKb(-) cells restores DSB repair function. Analysis of IKKb expression and IR-induced
phosphorylation of IkBa (A) and NFkB activation (B) in MCF-7 cells and MCF-7/IKKb (-) cells transfected with vector, wild-type (WT), kinase dead
(K44M), or a constitutively active form (SSEE) IKKb before (CTL) or 30 min after IR (2 Gy) by Western blots and an ELISA assay, respectively. The data
presented in (B) are mean 6 SE (n=3). *** p,0.001 vs. CTL. (C) and (D) Reconstitution of IKKb to MCF-7/IKKb(-) cells restores DSB repair function. DSBs
were analyzed by cH2AX and 53BP1 immunofluorescent staining at 1 h and 6 h after MCF-7 cells and MCF-7/IKKb (-) cells transfected with vector,
wild-type (WT), kinase dead (K44M), or a constitutively active form (SSEE) IKKb were exposed to 2 Gy IR. Un-irradiated cells were included as controls
(CTL). The average numbers of cH2AX and 53BP1 foci/cell from three independent experiments are presented in (C) and (D), respectively, as mean 6
SE. ** p,0.01, and *** p,0.001, vs. MCF-7 cells.
doi:10.1371/journal.pone.0018447.g005
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regulates the repair of IR-induced DSBs. Moreover, IKKb, but
not IKKa, is primarily responsible for promoting survival of
certain tumor cells after IR at least in part by facilitating DSB
repair. Surprisingly, NFkB-RelA is dispensable for IKKb-
dependent repair of DSBs. Therefore, IKKb inhibition or critical
processes involved in the IKKb-dependent DSB repair pathway
may be exploited as a novel therapeutic strategy to increase the
sensitivity of tumor cells to IR.
Materials and Methods
Reagents
TPCA-1, SC-514 and NU-7026 (NU) were purchased from
Calbiochem (San Diego, CA). KU-55933 (KU), BMS-345541
(BMS), Hoechst-33342 (Hoe) and Propidium iodide (PI) were
purchased from Sigma-Aldrich (St. Louis, MO).
Cell lines
MCF-7, H1299 and H1648 cell lines were originally obtained
from ATCC (Manassas, VA). They were selected for our study
because IR is a common therapeutic modality for breast and
lung cancer and these cell lines have been extensively used in
radiation research. MCF-7 cells stably transfected with the
dominant-negative mutant IkBa (mIkBa or IkBa A32/36) were
kindly provided by Dr. Jian Jian Li (University of California at
D a v i s ,S a c r a m e n t o ,C A ) .I m m ortalized wide type, IKKa,
IKKb,a n dI K K a/b double knockout mouse embryonic
fibroblasts were kindly provided by Dr. Shigeki Miyamoto
(University of Wisconsin-Madison, Madison, WI) with the
permission of Dr. Inder Verma (Salk Institute, La Jolla, CA).
All these cells were maintained in Dulbecco’s modified Eagle’s
minimum (DMEM) supplemented with 10% fetal bovine serum
( H y C l o n e ,L o g a n ,U T ) ,p e n i c i l l i n( 1 0 0U / m l )a n ds t r e p t o m y c i n
(100 mg/ml) in a humidified incubator (95% air/5% CO2)a t
37uC.
Construction of various IKKb expression vectors
PLVUT-tTR-KRAB lentiviral vector (Addgene, Cambridge,
MA) was digested with EcoRI and then ligated with synthetic
oligonucleotides containing PmeI, HpaI and BstBI sites to
generate PLVUT-1 vector. The PCR fragment containing PCMV
IE-GFP and BstBI sites was generated from pEGFP-C1 vector
(Clontech, Mountain View, CA) by PCR using PhusionH Hot
Start High-Fidelity DNA Polymerase (New England Biolabs,
Ipswich, MA). It was inserted into BstBI site of PLVUT-1 vector to
generate PLVUT-GFP vector. According to the sequences of
IKKb/WT, IKKb/K44M and IKKb/SSEE vectors (Addgene),
IKKb/WT, IKKb/K44M and IKKb/SSEE fragments contain-
ing PmeI and HpaI sites were generated by PCR using PhusionH
Hot Start High-Fidelity DNA Polymerase. PLVUT-GFP-IKKb/
WT, PLVUT-GFP-IKKb/K44M, PLVUT-GFP-IKKb/SSEE
lentiviral vectors were constructed after insertion of these
fragments into PmeI and HpaI sites of PLVUT-GFP vector.
The resulting vectors were confirmed by DNA sequence.
Lentivirus production
Lentivirus was produced after transient infection of human
embryonic kidney (HEK) 293T cells with individual lentiviral
vectors along with the packaging plasmids pCMV-VSV-G and
psPAX2 (Addgene) using FuGEN6-HD (Roche Diagnostics,
Mannheim, Germany) as the infection reagent according to
Roche’s protocol. The supernatants containing viral particles were
collected 48 h after the infection and filtered through 0.22 mm
filter. The viral particles were concentrated using a kit (PEG-itTM
Virus Precipitation Solution) from System Biosciences (Mountain
View, CA) according to the manufacturer’s instructions.
Ionizing radiation
Cells were exposed to various doses of IR in a JL Shepherd
Model 143
137Cesium -irradiator (JL Shepherd, Glendale, CA) at a
dose rate of 2.4 Gy/min. Cells were irradiated on a rotating
platform.
Figure 6. Inhibition of IKKb sensitizes MCF-7 cells to IR. (A)
Clonogenic survival of vector- or IKKa and/or IKKb shRNA-transfected
MCF7 cells after exposure to 0, 1, 2 and 3 Gy IR. (B) Clonogenic survival
of MCF-7 cells and MCF-7/IKKb (-) cells transfected with vector, wild-
type (WT), kinase dead (K44M), or a constitutively active form (SSEE)
IKKb after exposure to 0, 1, 2 and 3 Gy IR. (C) Clonogenic survival of
vehicle- or 2.5 mM BMS-345541 (BMS)-pretreated MCF-7 cells after
exposure to 0, 1, 2 and 3 Gy IR. The data are expressed as mean 6 SE
(n=3) of survival fraction compared to un-irradiated MCF-7 cells.
*** p,0.001.
doi:10.1371/journal.pone.0018447.g006
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Cells grown on a 4-chamber CultureSlide (BD Falcon, Bedford,
MA) after various treatments were fixed, permeabilized, and
stained as previously described [29]. The following antibodies
were used for the staining: 1:1000 mouse anti-phospho-H2AX
(cH2AX [Ser139], clone JBW301; Millipore, Billerica, MA) or
rabbit anti-53BP1 (cat# ab36823, from Abcam Inc., Cambridge,
CA) and 1:500 Alexa Fluor 568-conjugated anti-mouse IgG
(Cat#A11004, from Invitrogen, Camarillo, CA) or FITC-
conjugated anti-rabbit IgG (Cat# ab6767, from Abcam). Nuclei
were counterstained with Hoechst-33342. Approximately 200
nuclei images were acquired using a Zeiss Axio Observer.Z1
microscope with an Apo 60X/1.4 oil DICIII objective and
AxioVision (4.7.1.0) software (Carl Zeiss Microimaging Inc.,
GmbH, Jena; Germany). The numbers of cH2AX and/or
53BP1 foci for each cell was accounted, averaged and expressed
as cH2AX and/or 53BP1 foci/cell.
DNA-PK kinase assay
The kinase activity of DNA-PK was measured using a
SignaTECT DNA-Dependent Protein Kinase Assay System
(Cat# V7870, Promega, Madison, WI). The biotinylated peptide
substrate was incubated with 50 units purified DNA-PK (Cat#
V5811, Promega) and (c-
32P)ATP in the presence or absence of
BMS (5 or 10 mM) or NU (5 mM) for 5 min at 30uC according to
the manufacturer’s instructions. The biotinylated substrate was
captured on a streptavidin membrane, washed and quantified by a
Storm 860 Phosphorimager (Molecular Dynamics, Sunnyvale,
CA).
ATM kinase assay
ATM was purified from irradiated MCF-7 cells by immuno-
precipitation with anti-ATM antibody (Cat#A300-135A, from
BETHYL Laboratories, Montgomery, TX) as previously de-
scribed [30]. Aliquots of the purified ATM were incubated with
500 ng of recombinant H2AX (kindly provided by Dr. Benjamin
Chen, University of Texas Southwestern Medical Center, Dallas,
TX), 2 ml of 100 mM ATP and 10 mCi of (c-
32P)ATP in the
presence or absence of BMS (5 or 10 mM) or KU (5 mM) at 30uC
for 10 min. After SDS-polyacrylamide gel electrophoresis, c-
32P-
H2AX was visualized by autoradiography.
Knockdown of IKKa and/or IKKb with short hairpin RNA
(shRNA)
Control lentiviral pLKO.1 vector and pLKO.1 vectors
containing shRNAs for human IKKa (RHS4533-NM_001278)
and IKKb (RHS4533-NM_001556) were obtained from Open
Biosystems (Huntsville, AL). Viral particles were produced as
described above. To establish stable IKKa and/or IKKb
knockdown MCF-7 cell lines, MCF-7 cells were infected twice
with the viral particles under centrifugation (9006g)a t3 5 uC for
30 min. Stably transduced cells were selected with puromycin
(2 mg/ml). IKKa and/or IKKb knockdown in MCF-7/IKKa(-),
MCF-7/IKKb(-) and MCF-7/IKKa/b(-) cells, respectively, was
confirmed by Western blot.
Reconstitution of IKKb in MCF-7/IKKb(-) cell lines
MCF-7/IKKb(-) cells were infected twice with the viral particles
containing PLVUT-GFP vector or the vector encoding IKKb/
WT, IKKb/K44M and IKKb/SSEE as described above. The
cells expressing a moderate level of GFP were enriched twice by
cell sorting to generate stable MCF-7/IKKb(-)/vector, MCF-7/
IKKb(-)/WT, MCF-7/IKKb(-)/K44M, and MCF-7/IKKb(-)/
SSEE cell lines. The expression of IKKb in these cell lines was
confirmed using Western blot.
Western blot analysis
Total cell lysates were separated on 10% SDS–PAGE. The
proteins were transferred onto a PVDF membrane, blocked with
5% nonfat milk for 1 h at room temperature, and probed with a
primary antibody (1:1000) overnight at 4uC. The primary
antibodies used include anti-IKKa (Cat#2682), IKKb (Cat#
2678) and RelA (Cat# 4764) from Cell Signaling Technology
(Danvers, MA); and anti-phosphorylated IkBa (Cat# 2859), anti-
IkBa (Cat# 4814) and Actin (Cat# SC-1616) from Santa Cruz
Biotechnology (Santa Cruz, CA). The membranes were then
incubated with a horseradish peroxidase-conjugated secondary
antibody at 1:10,000 dilutions (Jackson ImmunoResearch Labs.,
West Grove, PA) for 1 h. Protein bands were visualized using
Amersham ECL Western Blotting Detection Reagents (GE
Healthcare, Piscataway, NJ) and exposed to ECL Plus film (GE
Healthcare).
NFkB RelA DNA-binding activity assay
Nuclear proteins were extracted from cells using the Nuclear
Extract Kit (from Active Motif, Carlsbad, CA) per the manufac-
turer’s protocol and were not contaminated by cytoplasmic
elongation factor 2 (EF2) based on the result of Western blot
using an antibody against EF2. NFkB-RelA DNA-binding activity
was determined by a TransAM
TM NFkB-RelA kit (Active Motif)
using 5 mg of nuclear extract proteins according to the
manufacturer’s instructions.
Down-regulation of RelA with small interference RNA
(siRNA)
To down-regulate the expression of RelA with siRNA,
5610
4 MCF-7 cells were seeded into a well of six-well plates.
After overnight incubation, the medium was removed and then
replaced with transfection media containing control (siGENOME
Non-Targeting siRNA, D-001210-02-05) or RelA (siGENOME
SMARTpool siRNA, M-003533-02-0005) siRNA (final concen-
tration 50 nmol/L) along with DharmaFECT4 transfection
reagent (Dharmacon) according to the manufacturer’s protocol.
After 24 h incubation, the transfection medium was removed and
replaced with cell culture medium. The cells were allowed to grow
for an additional 48 h to achieve maximal knockdown of RelA as
shown by real-time RT-PCR and Western blot analyses.
Real-time PCR
Real-time PCR was done as previously described using the
following primers: RelA, forward 59-CCTTCCTCATCC-
CATCTT TG- 39 and reverse 59-CCTCAATGTCCTCTTT-
CTGC-39; and GAPDH, forward 59-CCC CAC ACA CAT GCA
CTT ACC-39 and reverse 59-CCT ACT CCC AGG GCT TTG
ATT-39. The threshold cycle (Ct) value for RelA was normalized
to the Ct value of GAPDH. The relative RelA mRNA expression
was calculated using the comparative CT (2
-DDCt) method as
previously described [29].
Clonogenic survival assay
MCF-7 cells were seeded into wells of 12-well plates at 1610
4
cells/well. After overnight incubation, they were exposed to
various doses (0, 1, and 3 Gy) of IR with or without pretreatment
as indicated in individual experiments. The cells were allowed to
grow for additional 12 days to form colonies before stained with
0.1% crystal purple. Colonies with more than 50 cells were
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efficiency of control cultures.
Statistical analysis
The data were analyzed by analysis of variance (ANOVA). In
the event that ANOVA justified post hoc comparisons between
group means, these were conducted using the Student-Newman-
Keuls test for multiple comparisons. For experiments in which
only single experimental and control groups were used, group
differences were examined by unpaired Student t test. Differences
were considered significant at P,0.05. All of these analyses were
done using GraphPad Prism from GraphPad Software (San Diego,
CA).
Supporting Information
Figure S1 IKKb but not IKKa knockout inhibits the
repair of IR-induced DSBs in mouse embryonic fibro-
blasts. Mouse embryonic fibroblasts (MEF) from wild-type (WT),
IKKa, IKKb, and IKKa/b knockout mice were exposed to 2 Gy
IR. DSBs were analyzed by cH2AX and 53BP1 immunofluores-
cent staining at 1 h and 6 h after IR. Un-irradiated cells were
included as controls (CTL). Representative photomicrographs
(1006 magnifications) of cH2AX (red) and 53BP1 (green)
immunofluorescent staining and nucleic counterstaining with
Hoechst-33342 (blue) are shown in (A) and the average numbers
of cH2AX and 53BP1 foci/cell from three independent
experiments are presented (B) and (C) as mean 6 SE.
*p ,0.05, ** p,0.01, and *** p,0.001, vs. WT MEFs.
(TIF)
Figure S2 IKKb regulates DSB repair in a NFkB-RelA
independent manner. (A) and (B) Ectopic expression of mIkBa
inhibits IR-induced phosphorylation of IkBa and NFkB activation
in MCF-7 cells. The levels of phosphorylated IkBa (p-IkBa) and
total IkBa in the lysates from vector- or mIkBa-transfected MCF7
cells before (CTL) or 30 min after IR (2 Gy) were analyzed by
Western blots. NFkB activation was analyzed by quantification of
the levels of RelA in the nuclear extracts from vector- or mIkBa-
transfected MCF7 cells before (CTL) or 30 min after IR (2 Gy) by
an ELISA assay. The data presented in (B) are mean 6 SE (n=3).
*** p,0.001, vs. vehicle. (C) Ectopic expression of mIkBa has no
effect on the repair of IR-induced DSBs in MCF-7 cells. DSBs
were analyzed by cH2AX immunofluorescent staining at 1 and
6 h after vector- or mIkBa-transfected MCF7 cells were exposed
to 2 Gy IR. Un-irradiated cells were included as a control (CTL).
The average numbers of cH2AX foci/cell from three independent
experiments are presented as mean 6 SE. (D) Down-regulation of
RelA mRNA expression by siRNA was confirmed by real-time
PCR. The expression of RelA and GAPDH mRNA in RelA
siRNA-treated cells was expressed as a percentage of that in
control siRNA-treated cells. The data are presented as mean 6 SE
(n=3). *** p,0.001, vs. control siRNA treatment. (E) Down-
regulation of RelA expression by siRNA was confirmed by
Western blot in MCF-7 cells transfected with control (CTL) or
RelA siRNA. Un-transfected MCF-7 cells (Control) were included
as a control. (F) Down-regulation of RelA expression by siRNA
has no effect on the repair of IR-induced DSBs in MCF-7 cells.
DSBs were analyzed by cH2AX immunofluorescent staining at 1
and 6 h after control (CTL siRNA) or RelA siRNA-transfected
MCF7 cells were exposed to 2 Gy IR. Un-irradiated cells were
included as controls (CTL). The average numbers of cH2AX foci/
cell from three independent experiments are presented as mean 6
SE.
(TIF)
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